Wall Street expects Certara to report Q3 2026 revenue of $91.98 million and adjusted EPS of $0.09, as the stock trades at $10.90, roughly 19% above the consensus price target of $9.18. Investors are primarily focused on the growth of the high-margin software segment and whether it can offset ongoing stagnation in the company’s services revenue.
Management’s focus on biosimulation software and AI initiatives is seen as a long-term tailwind, though recent quarters have been pressured by a CFO transition and misses on the services side. Analysts will be listening for updates on the new Chief Commercial Officer's strategy to reaccelerate top-line growth and improve segment margins.